Latest Insider Positions


HOWARD RUDY is listed as an insider in the following companies: VTVT / vTv Therapeutics Inc Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Holdings

Security Title Post Shares
VTVT / vTv Therapeutics CFO & Secretary 5,000

Latest Transactions

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2015-08-04 VTVT / vTv Therapeutics P 5,000 5,000 15.00 75,000 75,000 100.00
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Peers of HOWARD RUDY include the following: ALTSTIEL LARRY DOUGLAS, BUCKLEY TIMOTHY, Barber Jeffrey T, CALDWELL DONALD R, CO INVESTMENT 2000 FUND LP, CO-INVESTMENT FUND II, L.P., CRAVEN PAMELA, CROSS ATLANTIC TECHNOLOGY FUND II LP, Co-Invest Capital Partners II, Inc., Co-Invest Capital Partners Inc, Co-Invest Management LP, Cohen Steven Michael, Collingsworth Grant W., Conway Thomas E, Cooke Albert C III, Cross Atlantic Capital Partners, Inc., FAISON RALPH E, FRY JOHN A, GAGNON NEIL, GILLIS DANIEL F, Harvey Kenneth M, Hendriks Elizabeth A, Ho Cho-Ying Davy, Holcombe Stephen L., Jamison Teresa, KINDLER JEFFREY B, Kaelin Jennifer G, Keister Douglas, MALONE JOHN, Nelson Steven, PERELMAN RONALD O, Parker Craig C, Pieri Nathan, Preuninger James W, SAVAS PAUL G, Sage Karen, Spiegel Noel Joseph, WIEHE STEPHEN J, Weiner Howard L., Williams Barry MV, XATF MANAGEMENT II LP, . Peers are determined by cross-linking the filings of HOWARD RUDY with insider filings of others at the same companies.

Related News Stories

Avoiding The 'Black Hole' Of Disease Development

2018-06-15 seekingalpha
Both large and small concerns continue to see nothing but failure in the Alzheimer's space despite spending billions on development efforts. (442-4)

Week In Review: Alibaba Transfers Assets To Ali Health In $1.4 Billion Deal

2018-06-03 seekingalpha
China's e-commerce giant Alibaba (NYSE:BABA) will transfer Ali JK Nutritional products into its online healthcare subsidiary, Alibaba Health (HK:0241), in exchange for $1.4 billion of Ali Health stock. Ali JK Nutritional sells medical devices, healthcare products, adult products, and healthcare services on Alibaba's Tmall platform. During the 12 months ending March 31, Ali JK generated $3.2 billion in sales from over 3,300 related merchants. (89-1)

Your Daily Pharma Scoop: Madrigal Zooms Ahead, Kitov Gets Approval, Mei Pharma's Results Are Positive

2018-06-01 seekingalpha
A little more than three months ago we extensively covered Madrigal Pharmaceuticals' (NASDAQ:MDGL) MGL-3196. Incidentally in that article we wrote “the last three months have seen gains of more than 230%.” And shareholders would have loved to see the same thing happen in the last three months. But that hasn’t happened. However what has happened is perhaps both more intriguing and interesting at the same time. (58-5)

How Newsoara Bio Is Saving vTv Therapeutics

2018-05-31 247wallst
vTv Therapeutics Inc. (NASDAQ: VTVT) shares saw a massive gain early on Thursday after the firm announced an exclusive licensing agreement with Newsoara Biopharma. This deal is for the rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries. (0-2)

Keeping It Simple On The Short Side

2018-05-11 seekingalpha
Today's Editor's Notes reviews five short ideas that each have a way of keeping it simple. (220-14)